Insilico Medicine, an AI-driven biotech company based in Hong Kong and in New York City, recently announced that its new AI-designed IBD drug — ISM5411 — has entered Phase I clinical trials.

In successful clinical trials of drugs for inflammatory bowel disease (IBD), patients who received a placebo were at ...

Explore how digital biomarkers are transforming clinical trials with real-time data, continuous monitoring and AI-driven ...

There are currently no cures for IBD. Clinical trials are necessary for finding new ways of preventing, detecting or treating diseases, but often, limited participation, especially from diverse ...

Rethinking Placebos in IBD Clinical Trials Patients with IBD assigned to placebo in clinical trials were shown to be at significantly higher risk for potential harms, according to two systematic ...

A recent study found that despite their growing presence in inflammatory bowel disease (IBD) research, women investigators were inequitably represented at scientific presentations sponsored by the ...

The research, published in Nature, gives an opportunity for health-care systems to pinpoint where their region sits on this ...

In the UC group, clinical remission rates were ... as Maintenance Therapy for Inflammatory Bowel Disease: 2 Randomized Phase 3 Trials, Gastroenterology (2024). DOI: 10.1053/j.gastro.

However, they added: "The results of this meta-analysis should prompt reflection on the current clinical trial model in IBD, encouraging critical thinking about possible strategies to minimise ...